Geron - Europe Partner
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Geron - Europe Partner
I didn't listen to CC this morning, but a few commenters on other boards indicated that Geron stated they will partner in Europe. Not a big surprise given lack of commercialization efforts before and after Rytelo approval. Under JS, the thinking seemed to be a partnership would not or could not occur without or until the IMpactMF P3 Trial was complete and approved. With interim results still not expected until mid 2026, this presents some interesting questions as to what a partnership would look like. Would the partnership be straight up LR-MDS indication only? Does partner get exclusive rights to negotiate terms for an additional indication MF and additional indications? Or, does Geron know enough about the IMpactMF Trial results thus far and can they share that information with a potential partner to do a complete deal?. Just thinking out loud.
-
biopearl123
- Posts: 2591
- Joined: Fri Jul 20, 2018 5:13 pm
Re: Geron - Europe Partner
Pretty clear they are seeking a EU partner and have their hands full with the US market. This is a good move and should have happened long ago.
Re: Geron - Europe Partner
From chatgpt ofc, I have followed other biotechs with less worthy drugs and they ended up using cro's for market access. From the call I didn't get any sense of excitement from mentioning europe.
Potential Ex-U.S. Partnership Options for Geron
Global Pharmaceutical Companies: Geron could consider partnerships with large pharmaceutical firms that have established international oncology portfolios and distribution networks. Companies such as Novartis, Roche, or AstraZeneca might be potential candidates, given their global reach and experience in hematologic malignancies.
Regional Pharmaceutical Firms: Collaborating with regional companies that have strong market presence in specific geographies (e.g., Europe, Asia-Pacific, Latin America) could be advantageous. These partners can provide localized expertise and regulatory knowledge.
Specialty Oncology Companies: Partnering with companies that specialize in oncology and have a focused approach to hematologic cancers might offer synergistic benefits. Such firms often have dedicated sales forces and established relationships with hematologists and oncologists.
Contract Research and Commercial Organizations (CROs and CCOs): Engaging with organizations that offer end-to-end services, from clinical development to commercialization, can be a strategic move, especially in markets where Geron lacks infrastructure.
Joint Ventures or Licensing Agreements: Forming joint ventures or entering into licensing agreements can provide Geron with the flexibility to share risks and benefits while leveraging the partner's strengths in specific markets.
Geron's prior experience with Janssen, despite its conclusion, provided valuable insights into large-scale collaboration. As the company advances imetelstat's development, especially with the anticipated U.S. launch, establishing ex-U.S. partnerships will be crucial for global commercialization.
You said:
which of these 5 options are the least likely to increase share price
ChatGPT said:
Among the five options listed, Contract Research and Commercial Organizations (CROs and CCOs) are the least likely to significantly increase Geron's share price, and here’s why:
1. Limited Market Excitement
CROs and CCOs provide services rather than strategic partnerships. Investors generally don’t view these arrangements as value-creating in the same way they do with high-profile commercial partnerships. There’s no upfront payment, royalties, or equity stake — just outsourced work.
2. No Shared Risk/Reward
CROs/CCOs don’t invest in the success of the product — they get paid regardless. This limits perceived upside and does not validate the commercial potential of the drug the way a licensing or co-commercialization deal with a pharma company would.
3. No Immediate Revenue Boost
Partnering with a CRO/CCO doesn’t usually bring in milestone payments or revenue-sharing agreements that would improve financials or spark bullish analyst sentiment.
By contrast:
Global or regional pharma partnerships often come with upfront cash, milestones, and royalties, which directly increase valuation.
Specialty oncology companies could add credibility and execution strength in a niche field.
Licensing deals or joint ventures often show a partner’s belief in the product, which tends to excite the market.
Potential Ex-U.S. Partnership Options for Geron
Global Pharmaceutical Companies: Geron could consider partnerships with large pharmaceutical firms that have established international oncology portfolios and distribution networks. Companies such as Novartis, Roche, or AstraZeneca might be potential candidates, given their global reach and experience in hematologic malignancies.
Regional Pharmaceutical Firms: Collaborating with regional companies that have strong market presence in specific geographies (e.g., Europe, Asia-Pacific, Latin America) could be advantageous. These partners can provide localized expertise and regulatory knowledge.
Specialty Oncology Companies: Partnering with companies that specialize in oncology and have a focused approach to hematologic cancers might offer synergistic benefits. Such firms often have dedicated sales forces and established relationships with hematologists and oncologists.
Contract Research and Commercial Organizations (CROs and CCOs): Engaging with organizations that offer end-to-end services, from clinical development to commercialization, can be a strategic move, especially in markets where Geron lacks infrastructure.
Joint Ventures or Licensing Agreements: Forming joint ventures or entering into licensing agreements can provide Geron with the flexibility to share risks and benefits while leveraging the partner's strengths in specific markets.
Geron's prior experience with Janssen, despite its conclusion, provided valuable insights into large-scale collaboration. As the company advances imetelstat's development, especially with the anticipated U.S. launch, establishing ex-U.S. partnerships will be crucial for global commercialization.
You said:
which of these 5 options are the least likely to increase share price
ChatGPT said:
Among the five options listed, Contract Research and Commercial Organizations (CROs and CCOs) are the least likely to significantly increase Geron's share price, and here’s why:
1. Limited Market Excitement
CROs and CCOs provide services rather than strategic partnerships. Investors generally don’t view these arrangements as value-creating in the same way they do with high-profile commercial partnerships. There’s no upfront payment, royalties, or equity stake — just outsourced work.
2. No Shared Risk/Reward
CROs/CCOs don’t invest in the success of the product — they get paid regardless. This limits perceived upside and does not validate the commercial potential of the drug the way a licensing or co-commercialization deal with a pharma company would.
3. No Immediate Revenue Boost
Partnering with a CRO/CCO doesn’t usually bring in milestone payments or revenue-sharing agreements that would improve financials or spark bullish analyst sentiment.
By contrast:
Global or regional pharma partnerships often come with upfront cash, milestones, and royalties, which directly increase valuation.
Specialty oncology companies could add credibility and execution strength in a niche field.
Licensing deals or joint ventures often show a partner’s belief in the product, which tends to excite the market.